• Market Capitalisation market-capitalisation-info $143 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-170 Mln

Mersana Therapeutics Inc. (MRSN) Share Price

$2.04

As on 04-Dec-2023 16:05 EST

up-down-arrow $0.147.37%

  • Prev Close info

    $1.90

  • Day's Openinfo

    $1.99

  • Today's Highinfo

    $2.05

  • Today's Lowinfo

    $1.77

  • Today's Volumeinfo

    3,601,450

  • 52 Week rangeinfo

    $0.80 - 9.62

Please wait...

Mersana Therapeutics Inc. (MRSN) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Mersana Therapeutics (MRSN)
-65.19 43.66 70.00 -71.86 -55.40 -17.23 --
S&P BSE Sensex*
13.73 7.51 5.44 10.07 15.35 13.88 12.82
S&P Small-Cap 600#
-5.82 -5.34 -13.90 -6.30 5.30 2.98 5.53
As on 04-Dec-2023  |  *As on 05-Dec-2023  |  #As on 26-Oct-2023
2022
2021
2020
2019
2018
Mersana Therapeutics (MRSN)
-5.79 -76.63 364.40 40.44 -74.98
S&P Small-Cap 600
-17.42 25.27 9.57 20.86 -9.70
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Mersana Therapeutics Inc. (MRSN) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Mersana Therapeutics Inc. (MRSN)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Mersana Therapeutics Inc. (MRSN)

        Pres, CEO & Director

        Ms. Anna Protopapas M.B.A.

        Sr. VP & CFO

        Mr. Brian C. DeSchuytner

        Headquarters

        Cambridge, MA

        FAQs for Mersana Therapeutics Inc. (MRSN)

        The total asset value of Mersana Therapeutics Inc. (MRSN) stood at $ 386 Mln as on 30-Jun-23

        The share price of Mersana Therapeutics Inc. (MRSN) is $2.04 (NASDAQ) as of 04-Dec-2023 16:05 EST. Mersana Therapeutics Inc. (MRSN) has given a return of -55.4% in the last 3 years.

        Mersana Therapeutics Inc. (MRSN) has a market capitalisation of $ 143 Mln as on 11-Aug-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Mersana Therapeutics Inc. (MRSN) is 7.14 times as on 11-Aug-2023, a 1.81% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Mersana Therapeutics Inc. (MRSN) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Mersana Therapeutics Inc. (MRSN) and enter the required number of quantities and click on buy to purchase the shares of Mersana Therapeutics Inc. (MRSN).

        Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

        The CEO & director of Ms. Anna Protopapas M.B.A.. is Mersana Therapeutics Inc. (MRSN), and CFO & Sr. VP is Mr. Brian C. DeSchuytner.

        The promoters of Mersana Therapeutics Inc. (MRSN) have pledged 0% of the total equity as on Mar-23.

        Mersana Therapeutics Inc. (MRSN) Ratios
        Return on equity(%)
        -239.78
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.28
        Dividend yield(%)
        0

        No, TTM profit after tax of Mersana Therapeutics Inc. (MRSN) was $-170 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $142.98 Mln
        • Revenue (TTM)revenue-information $38.72 Mln
        • Earnings (TTM) earning-information $-170.28 Mln
        • Cash date-information $444.44 Mln
        • Total Debt info $35.03 Mln
        • Insider's Holding 1.25%
        • Liquidity liquidity High
        • 52 Week range week-range $0.80 - 9.62
        • Shares outstanding share-outstanding 114,386,000
        • 8 Years Aggregate:

          CFO: $-407.73 Mln

          EBITDA: $-617.23 Mln

          Net Profit: $-625.44 Mln

        About The Company

        • IPO Date 28-Jun-2017
        • Pres, CEO & Director Ms. Anna Protopapas M.B.A.
        • Sr. VP & CFO Mr. Brian C. DeSchuytner
        • Listing key-listing NASDAQ: MRSN
        • Country United States
        • Headquarters headquarters Cambridge, MA
        • Website website https://www.mersana.com
        • Business

          Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an...  immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon